ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 308 filers reported holding ACADIA PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.65 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,527,806 | +8.7% | 505,173 | +25.0% | 0.04% | +7.9% |
| Q2 2023 | $9,682,721 | +106903.2% | 404,289 | -15.9% | 0.04% | -2.6% |
| Q1 2023 | $9,049 | +22.6% | 480,880 | +3.7% | 0.04% | +5.4% |
| Q4 2022 | $7,380 | -99.9% | 463,641 | +1.0% | 0.04% | -5.1% |
| Q3 2022 | $7,506,000 | +22.4% | 458,830 | +5.4% | 0.04% | +18.2% |
| Q2 2022 | $6,132,000 | -20.3% | 435,235 | +37.0% | 0.03% | -10.8% |
| Q1 2022 | $7,694,000 | +9.0% | 317,735 | +5.0% | 0.04% | +12.1% |
| Q4 2021 | $7,059,000 | +51.1% | 302,496 | +7.6% | 0.03% | +32.0% |
| Q3 2021 | $4,671,000 | -17.3% | 281,228 | +21.4% | 0.02% | -21.9% |
| Q2 2021 | $5,648,000 | +3992.8% | 231,584 | +4219.0% | 0.03% | +3100.0% |
| Q1 2021 | $138,000 | -9.2% | 5,362 | +87.0% | 0.00% | 0.0% |
| Q4 2020 | $152,000 | -38.0% | 2,868 | -51.9% | 0.00% | -50.0% |
| Q3 2020 | $245,000 | +24400.0% | 5,962 | +34970.6% | 0.00% | – |
| Q2 2020 | $1,000 | -50.0% | 17 | -75.0% | 0.00% | – |
| Q1 2019 | $2,000 | – | 68 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Fairmount Funds Management LLC | 432,317 | $11,154,000 | 4.70% |
| Baker Brothers Advisors | 41,910,704 | $1,081,296,000 | 4.69% |
| Palo Alto Investors LP | 2,337,877 | $60,317,000 | 3.44% |
| Birchview Capital, LP | 177,000 | $4,567,000 | 2.71% |
| Longitude (Cayman) Ltd. | 188,000 | $4,850,000 | 1.86% |
| GREAT POINT PARTNERS LLC | 311,217 | $8,029,000 | 1.66% |
| Avoro Capital Advisors LLC | 2,500,000 | $64,500,000 | 1.11% |
| PFM Health Sciences, LP | 1,302,129 | $33,595,000 | 1.03% |
| HealthCor Management, L.P. | 900,490 | $23,233,000 | 0.82% |
| Eversept Partners, LP | 420,000 | $10,836,000 | 0.82% |